Oculus Innovative Sciences, Inc, a healthcare company that develops, manufactures and markets a family of products based upon the Microcyn Technology platform, commercialized its Microcyn Skin and Wound Cleanser with preservatives in both professional and over-the-counter formulations. The professional product is indicated for use by health care practitioners to manage the debridement of wounds such as stage I-IV pressure ulcers, diabetic foot ulcers, post-surgical wounds, first- and second-degree wounds, grafted and donor sites. The OTC product is indicated for use in cleansing of dirt and debris from lacerations, skin abrasions, minor burns and minor irritations of the skin.

Microcyn Skin and Wound Cleanser with preservatives, which received FDA 510(k) clearance in May of this year, has demonstrated rapid activity against a broad spectrum of gram-positive, gram-negative and yeast species.

"These impressive in vitro kill times further validate the Microcyn Technology's unique and proprietary mode of action. At the same time, the Microcyn solution is safe as saline," said Hoji Alimi, founder and CEO of Oculus. "This safety profile simply can't be equaled by silver-based products or even Dakin's solution, better known as diluted bleach, which actually impede wound healing. We're excited to make these products commercially available so quickly after receiving our FDA clearance in May. As well, we are also sampling our new Microcyn hydrogel formulations to US physicians and are preparing to initiate a study of this proprietary hydrogel against other wound gels. We believe this data will provide the evidence necessary for a successful hard launch of the product into the medical community in early 2010."

Oculus, in partnership with its North American contract sales organization, Advocos, is marketing the Microcyn Skin and Wound Cleanser with preservative to medical professionals. The professional formulation is available in both 500 mL and 250 mL dosing bottles as well as an 8 oz. spray bottle.

Oculus is also currently sampling the new professional Microcyn Skin & Wound HydroGel formulation to US medical professionals. The OTC version of the HydroGel product will be available to consumers beginning October 2009.

Oculus Innovative Sciences develops, manufactures and markets a family of products based upon the Microcyn Technology platform, which includes new formulations designed to significantly reduce the need for antibiotics as it reduces infections.